← Issue №10/ week of Sep 6, 2026/Pancreas/Biliary

Clinical practice guidelines for duodenal cancer 2025.

From GI Signals issue №10: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Pancreas/Biliary guideline · Sep 5, 2026 · J Gastroenterology · IF 5.7

Clinical practice guidelines for duodenal cancer 2025.

Guideline / reviewguidelinepancreatic cancer
Clinical takeawayFollow updated guidelines for biopsy indications (e.g., [specific indications]), endoscopic treatment (consider lesion size [specific thresholds] and institutional experience [specific levels] for ESD), and consider gene panel testing for [specific biomarkers or genes] for personalized chemotherapy in duodenal cancer. Use specified techniques to prevent adverse events during endoscopic treatment.
What it foundRevised guidelines clarify indications for endoscopic treatment of non-ampullary duodenal epithelial tumors, provide specific biopsy indications (e.g., [specific indications from abstract]), and stratify ESD criteria by lesion size and institutional experience (e.g., [specific size thresholds and experience levels from abstract]). They also summarize minimally invasive surgery options and detail techniques for preventing adverse events in endoscopic treatment.
ContextUpdates and refines the 2021 guidelines with new evidence on endoscopic and surgical management, including specific criteria and techniques, and incorporates advances in personalized medicine based on [specific biomarkers or genes].
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Yasuda S … Sho M · Journal of Gastroenterology · IF 5.7 · PubMed ↗Permalink
← Read the whole of issue №10 Every paper GI Signals surfaces gets a page like this one. All issues